Prestige Consumer Healthcare Inc. (PBH) is a publicly traded company in the Healthcare — Medical - Pharmaceuticals industry listed on NYSE. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Prestige Consumer Healthcare Inc., along with its various divisions, is involved in the creation, production, promotion, and distribution of non-prescription health and personal care items across both domestic (U.S.) and global markets. The company's business activities are structured into two principal areas: North American Over-the-Counter Healthcare and International Over-the-Counter Healthcare.
Is Prestige Consumer Healthcare Inc. stock overvalued or undervalued in 2026?
Prestige Consumer Healthcare Inc. (PBH) trades at 13.4× earnings (P/E), below the median of the 246 healthcare companies over $2bn in Kaplio's universe. At its sector median (30.4×) $109 (+127 %).
Kaplio overview: Prestige Consumer Healthcare Inc.
Market cap $2B · 52 weeks $45 – $70 (32 % below the high) · P/E 13.4× · 2027 expected P/E 10.4× · Dividend none · Next earnings November 5, 2026 · expected EPS $1.07 · Closing price, Oct 28 · accounts published Aug 6.
- Valuation: P/E 13.4× (cheap).
- Business: ROIC 5 % (weak).
- Balance sheet: Net debt/EBITDA 3.0× (fragile).
- Earnings: 5 of 8 (uneven).
What would it be worth at its usual multiples?
At its sector median (30.4×) $109 (+127 %). Implied price from applying the reference multiples to today's earnings (or book value, or FFO) per share. Not a fair value: it is where the stock would trade at its usual multiples.
What matters in pharma: 2 of 7 pass
- R&D / Revenue 0.0 %, fails.
- 5y EPS growth 3.7 %, fails.
- Gross margin 52.8 %, fails.
- ROIC 4.8 %, fails.
- Net debt / EBITDA 3.0×, fails.
- FCF / Net Income 129.5 %, passes.
- P/E vs own 10y history 13.4×, passes.
Against its peers (reference peers) — Prestige Consumer Healthcare Inc.: P/E 13.4×; EV/EBITDA 13.6×; ROIC 4.8 %; $2.3B. Privia Health Group, Inc. (P/E 101×; EV/EBITDA —; ROIC 0.0 %; $2.8B), Catalyst Pharmaceuticals, Inc. (P/E 17.5×; EV/EBITDA 9.3×; ROIC 19.7 %; $3.9B), ICU Medical, Inc. (P/E 141×; EV/EBITDA 20.4×; ROIC -21.7 %; $4.2B).
Profitability
| Return on Equity | 9.22% |
| Return on Invested Capital | 4.80% |
| Return on Assets | 3.77% |
| Gross Margin | 53.26% |
| Operating Margin | 26.26% |
| Net Margin | 15.57% |
Financial Health
| Debt / Equity | 1.08 |
| Current Ratio | 3.23 |
| Piotroski F-Score | 5 |
| Altman Z-Score | 2.43 |
Price Performance
| 1 month | +2.25% |
| 3 months | -4.84% |
| Year-to-date | -22.53% |
| 1 year | -21.28% |
| 3 years | -18.89% |
| 5 years | -20.34% |
| 10 years | +5.54% |
Dividend History
| Date | Amount |
|---|---|
| 2018-09-27 | $0.4750 |
| 2013-12-27 | $0.3125 |
Amounts adjusted for stock splits.
Related companies: LIVN · LEGN · ICUI · PRVA · IRON · HTFL · ZLAB
Explore sector: Healthcare · Medical - Pharmaceuticals
More sections of PBH: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method today · Companies that pass the Lynch method today · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks